Q4 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Supernus Pharmaceuticals Inc (SUPN) reported a 25% increase in total revenues for 2024, excluding certain legacy products.
- Calvary, a core product, achieved a 72% growth in annual net sales and a 25% growth in annual prescriptions.
- The FDA approved an updated label for Calvary, highlighting its unique mechanism of action and providing important lactation data for breastfeeding women with ADHD.
- The company received a two-plus year patent term extension for Calvary, extending its patent protection to 2035.
- Supernus Pharmaceuticals Inc (SUPN) has a strong balance sheet with $454 million in cash and no debt, providing financial flexibility for potential M&A and growth opportunities.
- The first generic for Oxtellar XR entered the market, resulting in a decline in net sales for this legacy product.
- Combined net sales of Trokendi XR and Oxtellar XR were down 22% for the full year 2024.
- The phase 2B study of SPN-820 in adults with treatment-resistant depression did not demonstrate statistically significant improvement versus placebo.
- The company expects further erosion in sales of legacy products in 2025, with combined net sales projected to be between $65 million and $75 million.
- Operating earnings guidance for 2025 suggests a potential operating loss, with expectations ranging from $10 million in earnings to a $15 million loss.
Good afternoon and welcome to Supernus Pharmaceuticals fourth quarter and full-year 2024 financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to Peter Vozzo, IVR Healthcare, Investor Relations Representative for Supernus Pharmaceuticals. You may begin.
Thank you, Jacinda. Good afternoon, everyone, and thank you for joining us today for Supernas Pharmaceuticals fourth quarter and full-year 2024 financial results conference call. Today, after the close of the market, the company issued a press release announcing these results.
On the call with me today are Supernis's Chief Executive Officer Jack Guitar, and Chief Financial Officer Tim Deck. Today's call is being made available via the investor relations section of the company's website at ir.supernis.com.
During the course of this call, management may make certain forward-looking statements regarding future events and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
